Ublituximab (TG-1101) a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Combination with Ibrutinib is Highly Active in Patients with Relapsed and/or Refractory CLL and MCL: Results of a Phase II Trial. By admin / 12/09/2014
A Phase I Trial of Ublituximab, A Novel Glycoengineered Anti-CD20 mAb, In Combination With TGR-1202, A Next Generation PI3K Delta Inhibitor, In Patients With Chronic Lymphocytic Leukemia And Non-Hodgkin’s Lymphoma. By admin / 07/21/2014
Ublituximab (TG-1101), A Novel Glycoenginereed Anti-CD20 mAb, in Combination with Ibrutinib in Patients with CLL and MCL; Results of an Ongoing Phase II Trial. By admin / 06/13/2014
Ublituximab (TG-1101), A Novel Anti-CD20 Monoclonal Antibody for Rituximab Relapsed/Refractory B-Cell Malignancies. By admin / 06/13/2014
A Phase I Trial of Ublituximab (TG-1101), a Novel Anti-CD20 Monoclonal Antibody (MAB) in B-Cell Lymphoma Patients with Prior Exposure to Rituximab. By admin / 05/30/2014
Ublituximab (TG-1101), a Novel Anti-CD20 Monoclonal for Rituximab Relapsed/Refractory B-cell Malignancies. By admin / 06/14/2013
Final Results of a Multicenter Phase Ib Single Agent Study with the Novel Anti-CD20 Monoclonal Antibody Ublituximab (TG-1101) in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL). By admin / 06/04/2013
A Phase I Dose-Escalation Trial of Ublituximab (TG-1101), a Novel Anti-CD20 Monoclonal Antibody (mAb) for Rituximab Relapsed and/or Refractory C-Cell Lymphoma Patients. By admin / 06/02/2013
Ublituximab, an Optimized Anti-CD20 Monoclonal Antibody, Demonstrates Greater NK-Mediated ADCC Than Rituximab in Waldenstrom’s Macroglobulinemia Patients Supporting a Therapeutic Strategy with Ublituximab. By admin / 12/11/2012
Ublituximab (TGTX-1101), a Novel, Third-Generation Anti-CD20 Antibody Demonstrates Enhanced Antitumor Activity Compared to Rituximab in Primary CNS and Intraocular Lymphoma Murine Models. By admin / 12/11/2012
